<p>保德信金融公司在最近向證券交易委員會提交的 13F 表格中表示，在第二季度將其在 Haemonetics Corporation（紐約證券交易所代碼：HAE - 免費報告）的持股降低了 73.6%。該基金在季度內出售了 21,398 股後，持有 7,689 股這家醫療器械供應商的股票。截至其最近向證券交易委員會提交的文件，保德信金融公司在 Haemonetics 的持股價值為 574,000 美元。</p>
<p>其他大型投資者最近也對該公司的持倉進行了調整。Quarry LP 在第一季度將其在 Haemonetics 的股份增加了 63.4%。Quarry LP 現在擁有 495 股這家醫療器械供應商的股票，價值 31,000 美元，此前在該期間又購買了 192 股。GAMMA Investing LLC 在第二季度將其在 Haemonetics 的持股提高了 59.4%。GAMMA Investing LLC 現在擁有 443 股這家醫療器械供應商的股票，價值 33,000 美元，此前在上個季度又收購了 165 股。UMB Bank n.a.在第二季度將其在 Haemonetics 的股份增加了 91.7%。UMB Bank n.a.現在擁有 669 股這家醫療器械供應商的股票，價值 50,000 美元，此前又購買了 320 股。Parkside Financial Bank &amp; Trust 在第二季度將其在 Haemonetics 的持股增長了 11.6%。Parkside Financial Bank &amp; Trust 現在擁有 1,461 股這家醫療器械供應商的股票，價值 109,000 美元，此前又購買了 152 股。最後，Nisa Investment Advisors LLC 在第二季度將其在 Haemonetics 的持股增加了 85.4%。Nisa Investment Advisors LLC 現在擁有 1,470 股這家醫療器械供應商的股票，價值 110,000 美元，此前又購買了 677 股。目前 99.67% 的股票由機構投資者持有。</p>
<h2>分析師設定新目標價</h2>
<p>多家研究分析師最近對 HAE 股票發表了評論。BTIG Research 在 11 月 21 日的報告中重申了對 Haemonetics 的 “買入” 評級，並設定了 88.00 美元的目標價。花旗集團在 10 月 7 日的研究報告中將 Haemonetics 的目標價從 78.00 美元下調至 64.00 美元，並對該公司設定了 “買入” 評級。Weiss Ratings 在週一的研究報告中重申了對 Haemonetics 的 “持有（c-）” 評級。Raymond James Financial 在 11 月 14 日的研究報告中重申了對 Haemonetics 的 “跑贏大盤” 評級，並設定了 90.00 美元的目標價。最後，Wall Street Zen 在週六的研究報告中將 Haemonetics 的評級從 “持有” 上調至 “買入”。一位股票研究分析師對該股票給予了強烈買入評級，八位分析師給予了買入評級，兩位給予了持有評級，一位給予了賣出評級。根據 MarketBeat 的數據，該股票目前的平均評級為 “適度買入”，共識目標價為 79.70 美元。</p>
<p><strong>獲取我們關於 Haemonetics 的最新報告</strong></p>
<h2>Haemonetics 股票上漲 0.7%</h2>
<p>HAE 股票在週三開盤價為 83.83 美元。該股票的 50 日移動平均價格為 63.24 美元，200 日移動平均價格為 64.03 美元。Haemonetics Corporation 的 1 年最低價為 47.31 美元，1 年最高價為 85.48 美元。該公司的市值為 39.2 億美元，市盈率為 24.51，市盈率增長比率為 1.49，貝塔值為 0.30。該公司的債務與股本比率為 1.08，流動比率為 1.64，速動比率為 1.03。</p>
<p>Haemonetics（紐約證券交易所代碼：HAE - 獲取免費報告）最近於 11 月 6 日發佈了其財報。這家醫療器械供應商報告本季度每股收益為 1.27 美元，超出市場共識預期的 1.12 美元，超出幅度為 0.15 美元。Haemonetics 的淨利潤率為 12.67%，股本回報率為 27.22%。該公司本季度的收入為 3.2732 億美元，而市場共識預期為 3.1161 億美元。在去年同期，該公司每股收益為 1.12 美元。與去年同期相比，Haemonetics 的收入下降了 5.3%。Haemonetics 已將其 2026 財年的指引設定為 4.800-5.00 每股收益。研究分析師預計 Haemonetics Corporation 在當前財年將發佈 4.55 美元的每股收益。</p>
<h2>Haemonetics 公司簡介</h2>
<p>（免費報告）</p>
<p>Haemonetics Corporation 是一家醫療保健公司，在美國和國際上提供一系列醫療產品和解決方案。該公司提供自動化血漿採集系統、捐贈者管理軟件及支持軟件解決方案，包括 NexSys PCS 和 PCS2 血漿分離設備及相關耗材和解決方案，以及為血漿客户管理其捐贈者、運營和供應鏈的集成信息技術平台；以及 NexLynk DMS 捐贈者管理系統和 Donor360 應用程序。</p>
<h2>相關文章</h2>
<ul>
<li>我們更看好的五隻股票而非 Haemonetics</li>
<li>如何投資科技股及值得考慮的頂級科技股</li>
<li>消費者得到了煤炭，但聖誕老人給這兩家零售商帶來了巨大的收益</li>
<li>如何投資藍籌股</li>
<li>10 倍收益？這三隻機器人股票可能在 2035 年前爆發</li>
<li>納斯達克股票交易所是什麼？</li>
<li>安海斯 - 布希收購 BeatBox 以吸引年輕飲酒者</li>
</ul>
<p><strong>想看看其他對 HAE 持有的對沖基金嗎？</strong> 訪問 HoldingsChannel.com 獲取 Haemonetics Corporation（紐約證券交易所代碼：HAE - 免費報告）的最新 13F 文件和內部交易信息。</p>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPUhBRQ?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPUhBRQ"/></p>
<p><em>此即時新聞提醒由敍述科學技術和 MarketBeat 的金融數據生成，以便為讀者提供最快的報道和公正的覆蓋。請將任何問題或意見發送至 contact@marketbeat.com。</em></p>
<h2>你現在應該投資 1,000 美元在 Haemonetics 嗎？</h2>
<p>在考慮 Haemonetics 之前，你需要聽聽這個。</p>
<p>MarketBeat 每天跟蹤華爾街頂級評級和表現最佳的研究分析師及其推薦給客户的股票。MarketBeat 已經識別出五隻頂級分析師正在悄悄向客户推薦的股票，建議在更廣泛的市場注意到之前購買……而 Haemonetics 並不在名單上。</p>
<p>雖然 Haemonetics 目前在分析師中獲得了適度買入評級，但頂級分析師認為這五隻股票更值得購買。</p>
<p>在這裏查看這五隻股票</p>

保德信金融

<p>保德信金融公司在第二季度減少了對海蒙尼克斯公司的持股，減幅為 73.6%，目前持有 7,689 股，價值 574,000 美元。其他投資者調整了他們的持倉，Quarry LP、GAMMA Investing LLC、UMB Bank n.a.、Parkside Financial Bank & Trust 以及 Nisa Investment Advisors LLC 均增加了他們的股份。分析師對海蒙尼克斯的評級不一，普遍目標價為 79.70 美元。海蒙尼克斯報告第二季度每股收益為 1.27 美元，超出預期，但營收同比下降了 5.3%</p>

<p>Prudential Financial Inc. lowered its holdings in shares of Haemonetics Corporation (NYSE:HAE - Free Report) by 73.6% in the 2nd quarter, according to its most recent Form 13F filing with the Securities &amp; Exchange Commission. The fund owned 7,689 shares of the medical instruments supplier's stock after selling 21,398 shares during the quarter. Prudential Financial Inc.'s holdings in Haemonetics were worth $574,000 as of its most recent filing with the Securities &amp; Exchange Commission.</p>
<div class="lb-trans"><p>保德信金融公司在最近向證券交易委員會提交的 13F 表格中表示，在第二季度將其在 Haemonetics Corporation（紐約證券交易所代碼：HAE - 免費報告）的持股降低了 73.6%。該基金在季度內出售了 21,398 股後，持有 7,689 股這家醫療器械供應商的股票。截至其最近向證券交易委員會提交的文件，保德信金融公司在 Haemonetics 的持股價值為 574,000 美元。</p>
</div><p>Other large investors have also recently made changes to their positions in the company. Quarry LP boosted its stake in Haemonetics by 63.4% during the first quarter. Quarry LP now owns 495 shares of the medical instruments supplier's stock worth $31,000 after buying an additional 192 shares during the period. GAMMA Investing LLC lifted its holdings in shares of Haemonetics by 59.4% in the 2nd quarter. GAMMA Investing LLC now owns 443 shares of the medical instruments supplier's stock worth $33,000 after acquiring an additional 165 shares during the last quarter. UMB Bank n.a. boosted its stake in shares of Haemonetics by 91.7% during the 2nd quarter. UMB Bank n.a. now owns 669 shares of the medical instruments supplier's stock worth $50,000 after purchasing an additional 320 shares during the period. Parkside Financial Bank &amp; Trust grew its holdings in Haemonetics by 11.6% during the 2nd quarter. Parkside Financial Bank &amp; Trust now owns 1,461 shares of the medical instruments supplier's stock valued at $109,000 after purchasing an additional 152 shares during the last quarter. Finally, Nisa Investment Advisors LLC grew its holdings in Haemonetics by 85.4% during the 2nd quarter. Nisa Investment Advisors LLC now owns 1,470 shares of the medical instruments supplier's stock valued at $110,000 after purchasing an additional 677 shares during the last quarter. 99.67% of the stock is currently owned by institutional investors.</p>
<div class="lb-trans"><p>其他大型投資者最近也對該公司的持倉進行了調整。Quarry LP 在第一季度將其在 Haemonetics 的股份增加了 63.4%。Quarry LP 現在擁有 495 股這家醫療器械供應商的股票，價值 31,000 美元，此前在該期間又購買了 192 股。GAMMA Investing LLC 在第二季度將其在 Haemonetics 的持股提高了 59.4%。GAMMA Investing LLC 現在擁有 443 股這家醫療器械供應商的股票，價值 33,000 美元，此前在上個季度又收購了 165 股。UMB Bank n.a.在第二季度將其在 Haemonetics 的股份增加了 91.7%。UMB Bank n.a.現在擁有 669 股這家醫療器械供應商的股票，價值 50,000 美元，此前又購買了 320 股。Parkside Financial Bank &amp; Trust 在第二季度將其在 Haemonetics 的持股增長了 11.6%。Parkside Financial Bank &amp; Trust 現在擁有 1,461 股這家醫療器械供應商的股票，價值 109,000 美元，此前又購買了 152 股。最後，Nisa Investment Advisors LLC 在第二季度將其在 Haemonetics 的持股增加了 85.4%。Nisa Investment Advisors LLC 現在擁有 1,470 股這家醫療器械供應商的股票，價值 110,000 美元，此前又購買了 677 股。目前 99.67% 的股票由機構投資者持有。</p>
</div><h2>Analysts Set New Price Targets</h2>
<div class="lb-trans"><h2>分析師設定新目標價</h2>
</div><p>A number of research analysts have recently commented on HAE shares. BTIG Research restated a &#34;buy&#34; rating and issued a $88.00 price target on shares of Haemonetics in a report on Friday, November 21st. Citigroup lowered their price objective on shares of Haemonetics from $78.00 to $64.00 and set a &#34;buy&#34; rating for the company in a research report on Tuesday, October 7th. Weiss Ratings restated a &#34;hold (c-)&#34; rating on shares of Haemonetics in a research note on Monday. Raymond James Financial reaffirmed an &#34;outperform&#34; rating and set a $90.00 price target on shares of Haemonetics in a research note on Friday, November 14th. Finally, Wall Street Zen raised Haemonetics from a &#34;hold&#34; rating to a &#34;buy&#34; rating in a research note on Saturday. One equities research analyst has rated the stock with a Strong Buy rating, eight have assigned a Buy rating, two have given a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat, the stock currently has an average rating of &#34;Moderate Buy&#34; and a consensus target price of $79.70.</p>
<div class="lb-trans"><p>多家研究分析師最近對 HAE 股票發表了評論。BTIG Research 在 11 月 21 日的報告中重申了對 Haemonetics 的 “買入” 評級，並設定了 88.00 美元的目標價。花旗集團在 10 月 7 日的研究報告中將 Haemonetics 的目標價從 78.00 美元下調至 64.00 美元，並對該公司設定了 “買入” 評級。Weiss Ratings 在週一的研究報告中重申了對 Haemonetics 的 “持有（c-）” 評級。Raymond James Financial 在 11 月 14 日的研究報告中重申了對 Haemonetics 的 “跑贏大盤” 評級，並設定了 90.00 美元的目標價。最後，Wall Street Zen 在週六的研究報告中將 Haemonetics 的評級從 “持有” 上調至 “買入”。一位股票研究分析師對該股票給予了強烈買入評級，八位分析師給予了買入評級，兩位給予了持有評級，一位給予了賣出評級。根據 MarketBeat 的數據，該股票目前的平均評級為 “適度買入”，共識目標價為 79.70 美元。</p>
</div><p><strong>Get Our Latest Report on Haemonetics</strong></p>
<div class="lb-trans"><p><strong>獲取我們關於 Haemonetics 的最新報告</strong></p>
</div><h2>Haemonetics Stock Up 0.7%</h2>
<div class="lb-trans"><h2>Haemonetics 股票上漲 0.7%</h2>
</div><p>Shares of HAE stock opened at $83.83 on Wednesday. The stock's fifty day moving average price is $63.24 and its 200 day moving average price is $64.03. Haemonetics Corporation has a 1-year low of $47.31 and a 1-year high of $85.48. The company has a market cap of $3.92 billion, a price-to-earnings ratio of 24.51, a price-to-earnings-growth ratio of 1.49 and a beta of 0.30. The company has a debt-to-equity ratio of 1.08, a current ratio of 1.64 and a quick ratio of 1.03.</p>
<div class="lb-trans"><p>HAE 股票在週三開盤價為 83.83 美元。該股票的 50 日移動平均價格為 63.24 美元，200 日移動平均價格為 64.03 美元。Haemonetics Corporation 的 1 年最低價為 47.31 美元，1 年最高價為 85.48 美元。該公司的市值為 39.2 億美元，市盈率為 24.51，市盈率增長比率為 1.49，貝塔值為 0.30。該公司的債務與股本比率為 1.08，流動比率為 1.64，速動比率為 1.03。</p>
</div><p>Haemonetics (NYSE:HAE - Get Free Report) last released its earnings results on Thursday, November 6th. The medical instruments supplier reported $1.27 earnings per share for the quarter, topping the consensus estimate of $1.12 by $0.15. Haemonetics had a net margin of 12.67% and a return on equity of 27.22%. The company had revenue of $327.32 million for the quarter, compared to the consensus estimate of $311.61 million. During the same quarter in the previous year, the firm earned $1.12 EPS. Haemonetics's revenue was down 5.3% compared to the same quarter last year. Haemonetics has set its FY 2026 guidance at 4.800-5.00 EPS. On average, research analysts expect that Haemonetics Corporation will post 4.55 earnings per share for the current fiscal year.</p>
<div class="lb-trans"><p>Haemonetics（紐約證券交易所代碼：HAE - 獲取免費報告）最近於 11 月 6 日發佈了其財報。這家醫療器械供應商報告本季度每股收益為 1.27 美元，超出市場共識預期的 1.12 美元，超出幅度為 0.15 美元。Haemonetics 的淨利潤率為 12.67%，股本回報率為 27.22%。該公司本季度的收入為 3.2732 億美元，而市場共識預期為 3.1161 億美元。在去年同期，該公司每股收益為 1.12 美元。與去年同期相比，Haemonetics 的收入下降了 5.3%。Haemonetics 已將其 2026 財年的指引設定為 4.800-5.00 每股收益。研究分析師預計 Haemonetics Corporation 在當前財年將發佈 4.55 美元的每股收益。</p>
</div><h2>Haemonetics Company Profile</h2>
<div class="lb-trans"><h2>Haemonetics 公司簡介</h2>
</div><p>(Free Report)</p>
<div class="lb-trans"><p>（免費報告）</p>
</div><p>Haemonetics Corporation, a healthcare company, provides suite of medical products and solutions in the United States and internationally. The company offers automated plasma collection systems, donor management software, and supporting software solutions including NexSys PCS and PCS2 plasmapheresis equipment and related disposables and solutions, as well as integrated information technology platforms for plasma customers to manage their donors, operations, and supply chain; and NexLynk DMS donor management system and Donor360 app.</p>
<div class="lb-trans"><p>Haemonetics Corporation 是一家醫療保健公司，在美國和國際上提供一系列醫療產品和解決方案。該公司提供自動化血漿採集系統、捐贈者管理軟件及支持軟件解決方案，包括 NexSys PCS 和 PCS2 血漿分離設備及相關耗材和解決方案，以及為血漿客户管理其捐贈者、運營和供應鏈的集成信息技術平台；以及 NexLynk DMS 捐贈者管理系統和 Donor360 應用程序。</p>
</div><h2>Featured Articles</h2>
<div class="lb-trans"><h2>相關文章</h2>
</div><ul>
<li>Five stocks we like better than Haemonetics</li>
<li>How to Invest in Tech Stocks and Top Tech Stocks to Consider</li>
<li>Consumers Got Coal, But Santa Dropped Off Big Gains for These 2 Retailers</li>
<li>How to Invest in Blue Chip Stocks</li>
<li>10X Gains? These 3 Robotics Stocks Could Explode by 2035</li>
<li>What is the NASDAQ Stock Exchange?</li>
<li>Anheuser-Busch Buys BeatBox to Win Over Younger Drinkers</li>
</ul>
<div class="lb-trans"><ul>
<li>我們更看好的五隻股票而非 Haemonetics</li>
<li>如何投資科技股及值得考慮的頂級科技股</li>
<li>消費者得到了煤炭，但聖誕老人給這兩家零售商帶來了巨大的收益</li>
<li>如何投資藍籌股</li>
<li>10 倍收益？這三隻機器人股票可能在 2035 年前爆發</li>
<li>納斯達克股票交易所是什麼？</li>
<li>安海斯 - 布希收購 BeatBox 以吸引年輕飲酒者</li>
</ul>
</div><p><strong>Want to see what other hedge funds are holding HAE?</strong> Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Haemonetics Corporation (NYSE:HAE - Free Report).</p>
<div class="lb-trans"><p><strong>想看看其他對 HAE 持有的對沖基金嗎？</strong> 訪問 HoldingsChannel.com 獲取 Haemonetics Corporation（紐約證券交易所代碼：HAE - 免費報告）的最新 13F 文件和內部交易信息。</p>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPUhBRQ" alt="" original-src="https://www.marketbeat.com/scripts/SECFilingChart.ashx?Prefix=NYSE&amp;Symbol=HAE"/></p>
<p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即時新聞提醒由敍述科學技術和 MarketBeat 的金融數據生成，以便為讀者提供最快的報道和公正的覆蓋。請將任何問題或意見發送至 contact@marketbeat.com。</em></p>
</div><h2>Should You Invest $1,000 in Haemonetics Right Now?</h2>
<div class="lb-trans"><h2>你現在應該投資 1,000 美元在 Haemonetics 嗎？</h2>
</div><p>Before you consider Haemonetics, you'll want to hear this.</p>
<div class="lb-trans"><p>在考慮 Haemonetics 之前，你需要聽聽這個。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Haemonetics wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟蹤華爾街頂級評級和表現最佳的研究分析師及其推薦給客户的股票。MarketBeat 已經識別出五隻頂級分析師正在悄悄向客户推薦的股票，建議在更廣泛的市場注意到之前購買……而 Haemonetics 並不在名單上。</p>
</div><p>While Haemonetics currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>雖然 Haemonetics 目前在分析師中獲得了適度買入評級，但頂級分析師認為這五隻股票更值得購買。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在這裏查看這五隻股票</p>
</div>

保德信金融公司減少了其在 Heamonetics 公司的持股 $HAE